Literature DB >> 24009927

Evaluation of the need for treatment on 72 subjects with anti-HBe positive chronic hepatitis B.

Shima Soleimani Amiri1, Shariar Shafaee, Mohammad Reza Hasanjani Roushan, Masomeh Baiani, Mahmoud Hajiahmadi.   

Abstract

BACKGROUND: Viral load and alanine aminotransferase (ALT) levels may not be the key points for making a decision in the treatment of anti-HBe positive chronic hepatitis B. The purpose of this study was to assess the histological evaluation of liver to find the need for treatment on 72 patients with anti-HBe positive chronic hepatitis B.
METHODS: The liver biopsy slides of the 72 patients (56 subjects with viral load >10(5) with any ALT levels, 16 cases with viral load <10(5) copies/ml with abnormal ALT levels) were evaluated at the Department of Pathology, Babol University of Medical Sciences, Iran from April 2006 to August 2011. Ishak Scoring system was used to determine the hepatitis activity index (HAI) and fibrosis score. Those with total score >3 were considered for treatment. Data were collected and analyzed.
RESULTS: The mean age of the patients was 34.4±12 years. The mean ALT level was 105±10.5 IU/L. The mean HAI with viral loads more or less than >10(5) was 5.9±2.6 and 4±1.9, respectively (p=0.04). HAI >3 was seen in 9 (56.3%) and in 43 (76.8%) subjects with viral loads <10(5) and > 10(5) copies/ml (p<0.05). No fibrosis was seen in 25 (34.7%) of these cases. Fibrosis stage regarding viral loads more or less than10(5) copies/ml was equal (p=0.12). The need for treatment was seen in 62 (86%) patients.
CONCLUSION: The results show that any viral load values may cause significant injuries that need to treatment. Liver biopsy is indicated in any case of anti-HBe with any viral loads with increased ALT levels.

Entities:  

Keywords:  Fibrosis; Hepatitis activity index; Treatment; Viral load

Year:  2012        PMID: 24009927      PMCID: PMC3755863     

Source DB:  PubMed          Journal:  Caspian J Intern Med        ISSN: 2008-6164


  21 in total

1.  Chronic hepatitis B.

Authors:  A S Lok; B J McMahon
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

Review 2.  Management of hepatitis B: 2000--summary of a workshop.

Authors:  A S Lok; E J Heathcote; J H Hoofnagle
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

3.  Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

Authors:  Maurizia Rossana Brunetto; Filippo Oliveri; Piero Colombatto; Francesco Moriconi; Pietro Ciccorossi; Barbara Coco; Veronica Romagnoli; Beatrice Cherubini; Giovanna Moscato; Anna Maria Maina; Daniela Cavallone; Ferruccio Bonino
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

4.  Experts' opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.).

Authors:  Piero Luigi Almasio; Mauro Niero; Donato Angioli; Antonio Ascione; Sergio Gullini; Giorgio Minoli; Nadia C Oprandi; Giovan Battista Pinzello; Giorgio Verme; Angelo Andriulli
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 6.  Natural history of chronic hepatitis B and C.

Authors:  J C Imperial
Journal:  J Gastroenterol Hepatol       Date:  1999-05       Impact factor: 4.029

7.  Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B.

Authors:  M Lindh; P Horal; A P Dhillon; G Norkrans
Journal:  J Viral Hepat       Date:  2000-07       Impact factor: 3.728

8.  A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals.

Authors:  F ter Borg; F J ten Kate; H T Cuypers; A Leentvaar-Kuijpers; J Oosting; P M Wertheim-van Dillen; P Honkoop; M C Rasch; R A de Man; J van Hattum; R A Chamuleau; G N Tytgat; E A Jones
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

9.  Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.

Authors:  Emanuel K Manesis; George V Papatheodoridis; Vasilios Sevastianos; Evangelos Cholongitas; Christos Papaioannou; Stephanos J Hadziyannis
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

10.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.

Authors:  Guido Colloredo; Maria Guido; Aurelio Sonzogni; Gioacchino Leandro
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

View more
  1 in total

1.  Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier.

Authors:  Zohreh Azarkar; Azadeh Ebrahimzadeh; Gholamreza Sharifzadeh; Masood Ziaee; Mohammad Fereidouni; Fatemeh Taheri
Journal:  Caspian J Intern Med       Date:  2018
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.